Related Experiment Video

Updated: May 12, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

Chronic Lymphocytic Leukemia (CLL) with Borderline Immunoglobulin Heavy Chain Mutational Status, a Rare Subgroup of

Francesco Angotzi1, Alessandro Cellini1, Valeria Ruocco1

  • 1Hematology Unit, Department of Medicine, University of Padova, 35128 Padua, Italy.

Cancers
|March 28, 2024
PubMed

Insights

The borderline mutated immunoglobulin heavy variable (IGHV) subgroup in chronic lymphocytic leukemia (CLL) shows a short time to treatment like unmutated IGHV, but overall survival similar to mutated IGHV. Further research is needed for this rare CLL group.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) prognosis varies significantly.
  • Immunoglobulin heavy variable (IGHV) mutational status is a key prognostic factor, dividing patients into mutated (M-IGHV) and unmutated (U-IGHV) groups.
  • A rare borderline mutated IGHV (BL-IGHV) subgroup has been identified in approximately 5% of CLL cases.

Purpose of the Study:

  • To retrospectively analyze the clinical outcomes of BL-IGHV mutated CLL patients.
  • To compare time to first treatment (TTFT) and overall survival (OS) of BL-IGHV patients with M-IGHV and U-IGHV groups.
  • To investigate potential shared biological characteristics within the BL-IGHV subgroup.

Main Methods:

  • Retrospective analysis of 30 BL-IGHV mutated CLL patients within a larger cohort of 653 CLL patients.
  • Comparison of TTFT and OS between BL-IGHV, M-IGHV, and U-IGHV patient groups.
  • Analysis of prognostic factors and IGHV gene usage patterns.

Main Results:

  • BL-IGHV patients exhibited a short TTFT, comparable to U-IGHV patients (median 30.2 vs. 34 months).
  • The OS for BL-IGHV patients was similar to M-IGHV patients (median NR vs. 258 months).
  • Despite similar unfavorable prognostic factors, TTFT was shorter than in other published cohorts, suggesting unique biological traits.

Conclusions:

  • BL-IGHV mutated CLL patients present a distinct clinical profile with early treatment needs but favorable long-term survival.
  • Shared biological characteristics, including IGHV gene usage, may underlie the behavior of this rare CLL subgroup.
  • Multicentric studies are crucial to better understand BL-IGHV CLL, optimize treatment strategies, and improve outcome prediction for this challenging group.

Keywords:
IGHV mutational statusborderline mutatedchronic lymphocytic leukemia

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.7K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...